Sinobiopharma, Inc – SNBP
Sinobiopharma Inc. is an emerging, fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world’s fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company’s current therapeutic focus is on anaesthesia-assisted agents and cardiovascular drugs. Founded in 2004, Sinobiopharma employs more than 80 people at its corporate office and production facility in Nantong, China.
Sinobiopharma launched its extremely low-cost, Chinese patented new formulation of the pre-surgical skeletal muscle relaxant Cisatracurium Besylate on May 30, 2006. By October 2007, it had captured 80% of the Chinese market and was in use in more than 200 hospitals.
Investment Highlights
- Leadership of CEO, Dr. Lequn Lee Huang a former manager of the Bayer Co., one of the world’s largest pharmaceutical companies
- Diverse portfolio of marketed products and robust product pipeline
- Proven track record of product development and commercialization
- Strong financial management with CFO formerly of JP Morgan Chase and Smith Kline Beecham
- Patented technology for fast, low-cost synthesis of active pharmaceutical ingredients (API) enhances capability for rapid development of new drugs
- Proven R&D partners for collaborative drug discovery and established relationships with multinationals for outsourced drug development
- Nationwide sales and distribution network
R&D Strength
Sinobiopharma conducts research and development through Nanjing Su Ji Biotech Research Development Center and in cooperation with the Medicinal Chemistry Research Institute, Nanjing University. Both are located at Nanjing University in Nanjing. The city has emerged as one of China major biotech research and development centres. Sinobiopharma’s R&D team of 18 specialists (out of a total staff of 80) are highly experienced research personnel and medical professionals. They have given the Company a strong intellectual property base with six patents (see table below), primarily in the area of new methods for synthesizing compounds at lower cost, more rapidly and/or with greater ease of use. This strong R&D capacity, coupled with Sinobiopharma’s established links with multinational pharmaceutical companies makes the Company an attractive partner as a contract research organization (CRO).
Growth Strategy
Sinobiopharma has a clearly defined strategy to drive short, middle and long term growth. All drug development will leverage the Company’s patented technology for fast, low-cost drug synthesis and new technology for formulation.
In the Short Term, the focus is launching drugs new to the Chinese market. The Company’s patented synthesis method allows the company to develop new active pharmaceutical ingredients (API) at lower cost and new formulations that generally offer greater convenience in application and efficacy with fewer side effects.
The Middle Term will focus on exporting Active Pharmaceutical Ingredients and Drug Reformulations developed with the Company’s patented technology for the global market.
The Long Term will focus on applying the technology platform to identifying candidate compounds from Traditional Chinese Medicines. Such compounds have proven their safety and efficacy over thousands of years of use. Sinobiopharma will accelerate their discovery, synthesis and formulation for pharmaceutical applications.
Mission
Sinobiopharma’s vision is to become a world leader in the discovery, synthesis, formulation, manufacture, sale and distribution of safe, low-cost, high-efficacy biopharmaceuticals that combat for a wide range of diseases and conditions.
Sinobiopharma’s mission is to apply biotechnology to develop, manufacture and distribute innovate safe, low-cost, high efficacy biopharmaceuticals that help people live healthier lives while providing shareholders with significant, sustained return on investment.
Additional Links:
PennyStockSolutions.com Profile